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ImmunoprophylaxisThe efﬁcacy of a stabilized chemical analog of double-stranded ribonucleic acid (RNA), PIKA, as prophylaxis
against infection with 5 different inﬂuenza A virus subtypes, including the 2009 swine-origin pandemic
H1N1 virus, was evaluated in mice. Intranasal treatment with PIKA resulted in a signiﬁcant reduction of viral
replication in the respiratory tract. The inhibitory effect was mediated by rapid inﬁltration of immune cells
into the lungs, and production of inﬂammatory cytokines. While TLR3 is important for the optimal
production of these inﬂammatory cytokines, inhibition of viral replication was still observed in TLR3−/−
mice. In addition, a signiﬁcant synergistic effect in inhibiting H5N1 virus replication was observed when PIKA
was coadministered with oseltamivir. The broad-spectrum protection provided by PIKA makes it an
attractive option for prophylaxis from infection with inﬂuenza A viruses.3E13C.1, 33 North Drive, MSC
5719.
ao).
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Inﬂuenza is an acute respiratory disease associatedwith signiﬁcant
morbidity and mortality worldwide, particularly among the elderly
and young children (Izurieta et al., 2000; Neuzil et al., 2000; Nicholson
et al., 2003). The newly emerged swine-origin H1N1 virus has caused
the ﬁrst inﬂuenza pandemic of this century (Centers for Disease
Control and Prevention, 2009b). The enzootic of highly pathogenic
H5N1 inﬂuenza A viruses in poultry in Asia with sporadic transmis-
sion to humans also raises concerns of a possible pandemic (Beigel
et al., 2005; Lipatov et al., 2004). Vaccination is the most effective tool
for controlling an inﬂuenza pandemic, but it is estimated that the
global suppliers of vaccines can only produce ~2.5 billion doses within
the ﬁrst 12 months following receipt of a new vaccine strain and will
take 4 years to meet the global demand (International Federation of
Pharmaceutical Manufacturers & Associations, 24 February 2009).
While antiinﬂuenza drugs, such as neuraminidase inhibitors (oselta-
mivir and zanamivir) or ion channel blockers (adamantanes) have
been used for treatment and prophylaxis (Hayden et al., 1999;
Treanor et al., 2000), drug resistance occurs and the appearance of
drug resistant viruses before or during a pandemic would severely
affect the efﬁcacy of treatment strategies (de Jong et al., 2005;
Hayden, 2006a, b; Hurt et al., 2007; Kiso et al., 2004; Le et al., 2005;
McKimm-Breschkin et al., 2007). Therefore, additional antiviral
strategies are needed.In contrast to the adaptive immune system, the innate immune
system provides broad-spectrum defense that can be activated
immediately or within hours after infection. It is believed that these
antiviral responses play a critical role in limiting the replication and
dissemination of pathogens, providing time for adaptive immune
effectors to develop. For example, different innate cell types, such as
neutrophils (Fujisawa, 2008) and macrophages (Herold et al., 2008),
contribute to the control of inﬂuenza A virus replication in vivo and
plasmacytoid dendritic cells (pDCs) produce large amounts of type 1
interferon after exposure to inﬂuenza (Jego et al., 2003; Thitithanya-
nont et al., 2007).
We were interested in targeting innate immune mechanisms
because they may be less strain-speciﬁc than adaptive immune
mechanisms. We have previously demonstrated that the administra-
tion of a stabilized chemical analog of double-stranded (ds) RNA
(PIKA) was able to inhibit the replication of three mouse-adapted
laboratory strains (H1N1 and H3N1) of inﬂuenza A virus in mice (Lau
et al., 2009). In the current study, we extended these observations to
inﬂuenza A viruses with pandemic potential and variable virulence,
including three clinical isolates from humans, an H5N1 virus, an H9N2
virus, and a swine-origin H1N1 virus from the 2009 pandemic. Using a
number of assays, we also showed that a heightened antiviral state
was achieved in the respiratory tract shortly after administration of
the drug; several chemokines were produced and different cell types
inﬁltrated into the lungs. This study demonstrates the feasibility of
harnessing innate immunity to provide broad-spectrum protection
against multiple inﬂuenza A virus subtypes, an attractive approach as
a ﬁrst line of defense in the event of an inﬂuenza pandemic. We also
evaluated a combination of PIKA and oseltamivir for the prevention of
H5N1 virus infection in mice.
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Inhibition of viral replication in the respiratory tract of mice after PIKA
administration
We previously showed that after intranasal (i.n.) administration of
PIKA, pulmonary viral titers of three different laboratory strains of
inﬂuenza virus (A/Puerto Rico/8/34 (H1N1), A/WS/33 (H1N1), and a
reassortant of A/Memphis/1/71 (H3N1)) were substantially reduced
compared to a PBS control group (Lau et al., 2009). In this study, we
proceeded to evaluate the efﬁcacy of this strategy against ﬁve wild-
type (wt) inﬂuenza A viruses with pandemic potential. Groups of ﬁve
lightly anesthetized 8- to 10-week-old female BALB/c mice were
given 100 μg of PIKA or PBS, in a volume of 50 μL i.n. 6 hours before
infectionwith four avian inﬂuenza viruses, namely A/teal/HK/W312/
97 (H6N1), A/rhea/NC/93 (H7N1), A/HK/1073/99 (H9N2,) and A/
Vietnam/1203/2004 (H5N1), andwith an isolate from the 2009 H1N1
pandemic A/California/07/2009 (H1N1). Apart from the H5N1 virus,
for which the challenge dose was set at 15 TCID50 because it is
exceptionally virulent in mice, other viruses were administered at a
dose of 50 TCID50. Mice continued to receive daily treatment with
100 μg of PIKA i.n. for 2 days before theywere sacriﬁced on day 3 post-
infection (p.i.), and virus titers in nasal turbinates (NT) and lungs
were determined. As shown in Figs. 1A–E, the viruses replicated to
high titers in the lungs of mice treatedwith PBS. Lung virus titers were
statistically lower in mice that were treated daily with PIKA than in
the PBS control group (pb0.05, Mann–Whitney test). The efﬁcacy of
PIKA against the H6N1 virus could only be assessed in the lower
respiratory tract because the virus did not replicate to detectable
levels in the NT of mice. For the other viruses, 5/5 (H7N1), 3/5
(H9N2), 2/5 (H5N1), and 2/5 (H1N1) of the PBS-treated mice had
virus detected in the NT. Except for the H7N1 experiment in which
one mouse in the PIKA-treated group had virus detected in the NT,
none of the PIKA-treated mice in other challenge groups had virus
detected in the NT, demonstrating the effectiveness of the treatment
in inhibiting viral replication in the upper respiratory tract. InFig. 1. Administration of PIKA inhibited replication of inﬂuenza viruses in the respiratory tr
before challenge with the indicated viruses. The mice continued to receive PIKA treatment on
Virus titers in the lungs and NT were determined in MDCK cells. The lower limit of detection w
the group. The ‘*’ symbol indicates that the difference between the groups was statisticallysummary, the results suggest that PIKA prophylaxis can effectively
inhibit the replication of several subtypes of wt inﬂuenza A viruses
including the newly emerged H1N1 pandemic virus, leading to a
substantial reduction of viral titers in the respiratory tract.
Administration of PIKA protects mice from lethality following challenge
with A/Puerto Rico/8/34
To determine the signiﬁcance of the reduction in pulmonary virus
titer observed in our previous study (Lau et al., 2009) and in Fig. 1,
groups of ﬁve mice were treated with PIKA as previously described,
were challenged with 4 LD50 of A/Puerto Rico/8/34 and monitored
for 2 weeks. As shown in Figs. 2A and B, mice that received three doses
of PIKA were completely protected from lethal challenge with no
signiﬁcant weight loss and 100% survival, whereas all of the mice that
received PBS treatment demonstrated signiﬁcant weight loss and
succumbed to infection. In addition, virus-speciﬁc antibodies were
detected in the sera of the PIKA-treated mice on day 14 post-infection
(Fig. 2C).
Coadministration of PIKA with oseltamivir provides synergistic
protection against challenge with VN04 (H5N1) in mice
Although oseltamivir phosphate (Tamiﬂu) has been used widely
in treating infections with highly pathogenic H5N1 inﬂuenza A
viruses in humans, many patients still succumb to infection (Beigel
et al., 2005), and therefore, more effective treatment is needed. We
proceeded to determine the beneﬁt of coadministering PIKA with
oseltamivir for protection against H5N1 virus infection in mice.
Groups of ﬁve mice were given 100 μg of PIKA i.n. and 10 mg/kg/day
of oseltamivir by oral gavage 6 hours before challenge with 15 TCID50
of VN04 (H5N1, ~6 MLD50) wt virus i.n. The mice continued to
receive daily treatment with PIKA and two doses of oseltamivir
treatment daily. The dose of oseltamivir used was selected based on a
study by Yen et al. (2005) that demonstrated that a 5-day regimen of
10 mg/kg/day protected 50% of mice infected with 5MLD50 of VN04act of mice. Groups of ﬁve mice each were given 100 μg of PIKA in PBS intranasally 6 h
ce a day for two additional days. Lungs and NT were harvested on day 3 post-infection.
as 101.5 TCID50 per gram of tissue. The horizontal bars represent the geometric mean of
signiﬁcant (pb0.05).
Fig. 2. Administration of PIKA protected mice from lethal challenge and elicited inﬂuenza-speciﬁc antibody responses. (A and B) Groups of ﬁve mice each were given PIKA or PBS as
previously described and challenged with 4 LD50 of A/Puerto Rico/8/34 intranasally. The mice continued to receive PIKA treatment once a day for two additional days. Weight loss
and survival rate was monitored for 2 weeks. (C) Serum samples were collected from PIKA-treated mice on day 14 post-infection, and inﬂuenza-speciﬁc antibody titers were
determined by ELISA.
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replication in various organs was determined. This experimental
design allowed us to determine the virologic beneﬁt of the combined
therapy over oseltamivir treatment alone. We had also intended to
evaluate whether the combination of PIKA and oseltamivir would
offer a survival beneﬁt, but mice that received a 5-day course of
oseltamivir showed 60%–100% mortality on day 6 compared with
0%–20% mortality in a group that received water alone by gavage on
the same schedule, regardless of whether they were infected with an
inﬂuenza virus. We infer that the ﬁller material present in
commercial oseltamivir might contribute to the increased death
rate observed in mice because the dose of the drug is similar to that
reported (Yen et al. (2005).
As shown in Fig. 3A, challenging mice with 15 TCID50 of VN04
(H5N1) wt virus did not lead to signiﬁcant viral replication in the NT
on day 3 post-infection, even in mock-treated mice, and therefore, the
difference in the level of protection between the combined or
oseltamivir alone regimen did not reach statistical signiﬁcance.
However, none of the mice that received the combined treatment
had detectable levels of virus, while some mice that received
oseltamivir alone or mock-treated had virus detected in the NT (1/5
and 2/4, respectively). In the lungs, there was a signiﬁcant reduction
in pulmonary viral titers in mice that received the combined
treatment compared to the groups that received oseltamivir alone
or mock treatment (Fig. 3B; pb0.05, Mann–Whitney test). Three outFig. 3. Synergistic antiviral effect achieved against H5N1 infection in mice by
coadministering PIKA with oseltamivir. (A and B) Groups of ﬁve mice were given
either oseltamivir alone by oral gavage or together with 100 μg of PIKA i.n. 6 hours
before challenge with 15 TCID50 of VN04 wt.Mice continued to receive treatment for 2
additional days. NT and lungs were harvested for viral titration on day 3 post-infection.
Virus titers in the NT (A) and lungs (B) were determined in MDCK cells. The lower limit
of detection was 101.5 TCID50 per gram of tissue. The horizontal bars represent the
geometric mean of the group. The ‘*’ symbol indicates that the difference between the
groups was statistically signiﬁcant (pb0.05).of ﬁve mice that received the combined treatment had no detectable
virus in their lungs on day 3 post-infection, and the average viral titer
was lower than the group that received oseltamivir alone (Fig. 3) or
PIKA alone (Fig. 1D). These results suggest that targeting different
antiviral mechanisms is a feasible approach in achieving a synergistic
virologic effect in combating H5N1 virus infection.
Administration of PIKA led to changes in the cellular composition and
chemokine production in the lungs of mice
To establish the mechanism(s) responsible for the reduction in
viral titers achieved by PIKA, mice that were given one or three doses
of PIKA were sacrﬁced at various time points to examine the lungs for
changes in cellularity. Single-cell suspensions were made as previously
described (Lau et al., 2006), and different cell populations were
identiﬁed using cellular markers conjugated with ﬂuorochromes (See
Supplemental Figure 1 for the gating strategy). Using this approach, we
were able to identify ~70% of the cell population in the lungs (data not
shown). As shown in Fig. 4A, there was a two-fold increase in
neutrophils (CD11b+ CD11c−, Ly6G+, Ly6C+) within 24 hours of a
single dose of PIKA, reaching a peak on day 2 post-administration. The
number of neutrophils in the lungs of mice after three doses of PIKA
was signiﬁcantly greater than in mice that received a single dose of the
drug (pb0.05, unpaired t test). There was an inﬁltration of interstitial
macrophages (CD11bHi, CD11cLo) in the lungs that peaked on day 1
post-inoculation and was maintained at an elevated level for the next
72 hours (Fig. 4B). On the other hand, the inﬁltration of pDCs (CD11c+,
Gr-1+, B220+; Nakano et al., 2001) into the lungs was more gradual,
continuing to increase for 72 hours after a single dose of PIKA (Fig. 4C).
Administration of three consecutive doses of PIKA led to a signiﬁcant
increase in both interstitial macrophages and pDCs (pb0.05, unpaired
t test). However, there was a reduction in the number of alveolar
macrophages (CD11cHi, CD11bLo) within 24 hours of PIKA treatment
that was maintained for 72 hours (Fig. 4D). There were no signiﬁcant
changes in the numbers of natural killer cells, NKT cells, B lymphocytes,
and CD4+ and CD8+ T lymphocytes in the lungs (data not shown).
Since cytokines and chemokines are responsible for cellular
migration, we examined the levels of different cytokines and
chemokines in the lungs at different time points after a single dose
of PIKA. The lungs were homogenized and clariﬁed homogenates
were analyzed in duplicate with the Bio-plex Protein Array system to
determine the protein levels of cytokines and chemokines. As shown
in Fig. 5A, an early response of TNF-α was seen, with an increase
6 hours after administration of PIKA and return to baseline by
48 hours. The production of other cytokines such as IFN-γ, Rantes,
MCP-1, and MIP-1b, increased 6 hours following administration of
Fig. 4. Administration of PIKA changed the cellular composition of the lungs. Groups of three mice were given 100 μg of PIKA i.n. in PBS and sacriﬁced 1, 2, or 3 days later. An
additional group received 100 μg of PIKA i.n. once a day for 3 consecutive days, and mice were sacriﬁced 24 hours after the last inoculation. Single-cell suspensions were prepared,
and the cells were stained with the indicated cellular makers. Eighty thousand events were acquired for each sample. The bars and error bars represent themean and standard errors
of the groups. The ‘*’ symbol indicates that the difference between the groups was statistically signiﬁcant (pb0.05).
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increase in production of KC was observed at 24 and 48 hours
following PIKA administration (Fig. 5C). In addition, there was an
increase in the production of IFN-β in lungs 24 hours after
administration of PIKA (Fig. 5D). In summary, these data suggest
that intranasal administration of PIKA leads to the activation of innate
immunity in the respiratory tract, leading to inﬁltration of the lungs
by immune cells and the production of cytokines and chemokines that
are associated with inhibition of viral replication in the respiratory
tract of mice.
TLR3 is dispensable in mediating the antiviral response to PIKA in mice
Using a plasmid expression system, we previously showed that
PIKA interacts with TLR3 (Lau et al., 2009). Using the same expressionFig. 5. Administration of PIKA induced production of cytokines in the lungs. Groups of three m
The lungs were stored at−80 °C till all samples were collected and homogenized in 1 mL of
samples, 50 μL of the clariﬁed samples was tested in duplicate using the Bio-plex Protein Arr
The bars and error bars represent the mean and standard error of the groups.system, we showed that, in addition to TLR3, PIKA can also be
recognized by melanoma differentiation-associated gene 5 (MDA-5)
and retinoic acid-inducible gene I (RIG-I) (Fig. 6A). Since TLR3 has
been identiﬁed as a receptor for dsRNA with abundant expression in
the lungs (Alexopoulou et al., 2001), micewith a targeted defect in the
TLR3 gene were used to determine the role of TLR3 in mediating the
antiviral effect of PIKA. TLR3−/− and TLR3+/+mice were given 100 μg
of PIKA or PBS intranasally, and the concentrations of various
cytokines in lung homogenates were determined. As shown in
Fig. 6B, compared with TLR3+/+ mice, the TLR3−/− mice showed a
general trend of diminished cytokine production. The level of
reduction varied between cytokines, with no increase of TNF-α and
IFN-γ detected in TLR3−/− mice after PIKA stimulation. For other
cytokines such asMIP-1b, Rantes, andMCP-1, there was an increase in
production in TLR3−/−mice in response to PIKA treatment; however,ice each were given 100 μg of PIKA i.n. in PBS and were sacriﬁced at the indicated time.
RPMI-1640 media. (A–C) To measure the level of different cytokines/chemokines in the
ay system. (D) For IFN-β, 100 μL of the clariﬁed samples were tested using an ELISA kit.
Fig. 6. TLR3 is dispensable in mediating the antiviral responses of PIKA in mice. (A) Human embryonic kidney (HEK 293 cells) were transfected with an NF-κB-luciferase reporter
gene and a β-galactosidase-expressing plasmid with or without co-transfection of the indicated TLR3, MDA-5, or RIG-I receptor-expressing plasmids. Twenty-four hours after
transfection, the cells were stimulated with 50 ng of PIKA in plainmedium for 6 hours before the cells were lysed, and luciferase activity in the lysates was determined. The data were
normalized to β-galactosidase activity and expressed as fold increase relative to expression in cells that were transfected with respective receptor-expressing plasmids without PIKA
stimulation. The bar and error bars represent themean and standard error of eight replicates and are representative of two independent experiments. (B) Groups of three TLR3−/− or
TLR3+/+mice received PIKA or PBS intranasally and were sacriﬁced 24 hours later. Lung homogenates were prepared, and the concentration of various cytokines was determined as
previously described. Data are expressed as the fold increase in PIKA-treated mice over PBS-treated mice. Groups of ﬁve TLR3−/− or TLR3+/+ mice received PIKA and were
challenged with the H7N1 virus as previously described. Virus titers in the NT (C) and lungs (D) were determined inMDCK cells. The horizontal bars represent the geometric mean of
the group. The ‘*’ symbol indicates that the difference between the groups was statistically signiﬁcant (pb0.05).
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with the difference for Rantes reaching statistical signiﬁcance
(pb0.05). The production of KC and IFN-β was comparable between
the two strains of mice. The results suggest that TLR3 is important for
optimal cytokine production in response to PIKA. To determine the
impact of the diminished cytokine responses on the antiviral effect of
PIKA, TLR3−/−micewere treatedwith PIKA or PBS andwere challenged
with 50 TCID50 of the H7N1 virus. This virus was chosen because it was
able to replicate to high titer in both the upper and lower respiratory
tracts ofmice (Fig. 1B), allowingus to determine the importance of TLR3
in both areas. As shown in Fig. 6C, the virus replicated to high titer in the
NT in the TLR3−/−mice treatedwith PBS, and the titer was signiﬁcantly
higher than in mice treated with PIKA (pb0.05, Mann–Whitney test).
The virus titers in the lungs of the TLR3−/−micewere variable (Fig. 6D),and the mean titer in the two groups of mice was not statistically
different. The results suggest that the production of cytokines induced
by PIKA in the absence of TLR3 signaling was still sufﬁcient to inhibit
viral replication in vivo.
Discussion
We have demonstrated the efﬁcacy of PIKA against different
inﬂuenza A virus subtypes with pandemic potential that have caused
infections in humans, including the newly emerged 2009 H1N1
pandemic virus (Butt et al., 2005; Centers for Disease Control and
Prevention, 2009b; de Jong et al., 2005; Peiris et al., 1999; Subbarao
et al., 1998). Although it may seem obvious that a drug that induces an
interferon-induced antiviral state would prevent infection by
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against viruses of varied virulence is important, and the virologic
beneﬁt of combining PIKA prophylaxis with oseltamivir is novel. We
have also explored the mechanism underlying the antiviral effects of
PIKA.
While immunoprophylaxis with poly IC has been described using
mouse-adapted inﬂuenza strains (Saravolac et al., 2001; Wong et al.,
1995, 1999), the mechanism responsible for the antiviral effects has
not been studied in detail. Our data show that a number of immune
effectors were activated following intranasal administration of PIKA.
The initial wave of cytokine production occurred 6 hours following
administration of PIKA included cytokines TNF-α and IFN-γ that have
antiviral properties (Seo andWebster, 2002). Inﬂammatory cytokines,
such as Rantes (CCL5) (Dorner et al., 2002) andmonocyte chemotactic
protein-1 (MCP-1), were produced in response to PIKA and led to the
recruitment of effector cells such as neutrophils, macrophages, and
pDCs into the lungs within 24 hours of administration of a single dose
of PIKA. Fujisawa et al. (1987) have demonstrated the important role
of polymorphonuclear leukocytes (PMN) in the early response to
inﬂuenza virus infection, and Hashimoto et al. (2007) demonstrated
that neutrophils and macrophages were capable of phagocytosing
inﬂuenza-induced apoptotic cells in vivo, thereby disrupting the
infectious cycle of the virus. Several investigators have used
monoclonal antibodies to deplete neutrophils and/or macrophages
in vivo and found an increase in viral titers associated with severe
clinical disease (Tate et al., 2008; Tumpey et al., 2005). pDCs have the
ability to produce large amounts of type 1 IFNs after exposure to
inﬂuenza virus (Jego et al., 2003; Thitithanyanont et al., 2007,) and the
release of type 1 IFNs can lead to the activation of IFN-stimulated
genes with antiviral functions, such as Mx proteins, protein kinase R,
and 2′5′ oligoadenylate synthetase (reviewed in Samuel, 2001). Since
it is more difﬁcult for pathogens to simultaneously develop resistance
to two or more pathways than to a single pathway, the induction of
antiviral effects by multiple pathways reduces the likelihood of
viruses becoming resistant to PIKA. In addition, we demonstrated that
the synergism achieved by coadministering PIKAwith oseltamivir was
sufﬁcient to inhibit viral replication of the H5N1 virus (Figs. 1D and 3).
Because the strategy of activating generic antiviral mechanisms by
targeting the innate immune system is effective against a number of
viruses, including herpes simplex virus type-2 (Bernstein et al., 2001;
Harrison et al., 1994), cytomegalovirus (Chen et al., 1988), parain-
ﬂuenza (Stokes et al., 1998), West Nile virus (Morrey et al., 2004), and
inﬂuenza virus (Wong et al., 2005, 2007), we believe PIKA may have
the potential to inhibit the growth of other viral pathogens.
While the antiviral properties of dsRNA compounds, such as poly
ICLC, have been well documented, they are often associated with side
effects. In a study by Wong et al. (1999), mice showed ~11% weight
loss and hypothermia after receiving two doses of poly ICLC (~20 μg
per dose). In contrast, PIKA displays antiviral properties in mice
without causing signiﬁcant weight loss. Although TLR3 has been
identiﬁed as a receptor for dsRNA and cells from TLR 3−/− mice
showed reduced responses to poly I:C in vitro (Alexopoulou et al.,
2001; De Miranda et al., 2009), our experiment in TLR3−/− mice
suggested that other receptors might also be involved in mediating
the antiviral activity of PIKA. Arimura (1975) and Kato et al. (2008)
demonstrated that the interferon-inducing activity and recognition by
RIG-I and MDA-5 of Poly I:C are dependent on the length of the poly I:
C molecules. PIKA contains dsRNA greater than 100 bp in size (Peter
Brazier, unpublished data), its receptor usage in vivo might be
different from those used by poly I:C due to different size distribution.
In addition, while Gitlin et al. (2006) reported thatMDA-5, rather than
TLR3, played an important role in mediating the type 1 interferon
response to poly I:C in vivo, others showed that both MDA-5 and TLR3
are required for optimal biological activity of poly I:C (Kumar et al.,
2008; Trumpfheller et al., 2008). The contradictory results could be
because poly I:C was administered by different routes in these studies.We were unable to determine the relative importance of RIG-I and
MDA-5 on the antiviral effect of PIKA in vivo, and we are currently
investigating how PIKA can access MDA-5 and RIG-I, which are
cytosolic sensors.
In an inﬂuenza challenge experiment using TLR3−/− and wild-
type mice, Le Gofﬁc et al. (2006) demonstrated that TLR3 activation in
the context of an inﬂuenza virus infection resulted in an increase in
cytokine production and the number of inﬂammatory cells in the
lungs, resulting in immunopathology and reduced survival. The
sequence of events in our experiments was different: mice were
pretreated with PIKA that induced TLR3 activation and cytokine
production. When the mice were subsequently infected with
inﬂuenza virus, there was reduced viral replication, less inﬂammation
and improved survival. In our lethal challenge experiment, the mice
pretreated with PIKA showed no signiﬁcant weight loss after
infection, an observation that is markedly different from Le Gofﬁc's
study. We speculate that timing of TLR3 activation relative to
inﬂuenza virus infection determines the outcome.
Wong et al. (2009) reported recently that administration of dsRNA
condensed with poly-L-lysine and carboxymethylcellulose improved
the survival of mice challenged with a lethal dose of A/chicken/
Henan/5/2004 (a clade 2 H5N1 virus). In addition, Tuvim et al. (2009)
showed that induction of local pulmonary inﬂammation led to
protection against inﬂuenza infection in mice. Our ﬁndings further
extend these observations by demonstrating the breadth of protection
that PIKA can provide against a range of inﬂuenza viruses with
pandemic potential. Furthermore, the transient inhibition of viral
replication mediated by PIKA allows mice to be primed and develop
inﬂuenza-speciﬁc antibody responses that can provide long-term
protection from reinfection. A number of studies have shown that
intranasal administration of exogenous type I interferon protects
mice, ferrets, and guinea pigs from inﬂuenza virus infection (Kugel
et al., 2009; Tumpey et al., 2007; Van Hoeven et al., 2009). Activation
of the innate immune system using synthetic compounds to induce
endogenous type I interferon productionmight be more cost-effective
than exogenous type I interferon administration.
Since it remains uncertain which inﬂuenza strain(s) will eventu-
ally emerge as a pandemic virus, drugs that target the innate immune
system and provide broad-spectrum antiviral activity have the
potential to be used as a ﬁrst line of defense. Our ﬁndings are
promising and provide support for further evaluation of PIKA for
prophylaxis. Areas for further study include an assessment of the risk
of immunologic tolerance resulting from stimulation of the innate
immune system (Trinchieri and Sher, 2007), the risk of secondary
bacterial infection that is a common complication of inﬂuenza virus
infection (Centers for Disease Control and Prevention, 2009a; Morens
et al., 2008; Sun and Metzger, 2008), and studies to establish the
feasibility of using PIKA prophylaxis in humans including the timing
and duration of treatment.
Materials and methods
Mice
In all mouse experiments, 6- to 8-week-old female BALB/c mice
(Taconic Farms, Inc., Germantown, NY) were used. The B6;129 S1-
Tlr3tm1Flv/J (stock number 005217) and B6129SF2/J (stock number
101045) were purchased from The Jackson Laboratory (Bar Harbor,
ME). The animal protocols were approved by the National Institutes of
Health's Animal Care and Use Committee, and the experiments were
conducted at the NIH.
Viruses
Viruses used in this study were kindly provided by Dr Robert G.
Webster, St. Jude Children's Research Hospital, Memphis, TN; Dr
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Prevention, Atlanta, GA; and Dr David Swayne, Southeast Poultry
Research Laboratory, USDA, Athens, GA. Virus stocks were propagated
in the allantoic cavity of 9-day-old embryonated speciﬁc pathogen-
free hen's eggs (Charles River Laboratories, Wilmington, MA) at 37 °C.
Clariﬁed allantoic ﬂuids were aliquoted and stored at −80 °C.
Administration of PIKA and oseltamivir phosphate
PIKA was obtained from NewBiomed PIKA Pte Ltd. (Singapore).
The endotoxin level of the lot of PIKA used in this study was
determined by an independent accredited laboratory and was b1
endotoxin unit/mg of PIKA. Mice were lightly anesthetized with 4%
isoﬂurane and inoculated intranasally with 100 μg of PIKA in 50 μL of
sterile PBS. Control mice received 50 μL of sterile PBS. Oseltamivir
phosphate (Tamiﬂu, 75 mg; Roche, NJ) was obtained from a local
pharmacy. The contents of the 75-mg capsules were emptied from the
shell and dissolved in water. Mice were given oseltamivir by oral
gavage twice daily at 10 mg/kg/day in a volume of 200 μL for 3 days.
Control mice received sterile water on the same schedule.
Viral titration assay
Lungs and nasal turbinates were harvested, weighed, and homog-
enized in L-15 medium to prepare a 10% wt./vol. tissue homogenate.
Thematerialswere clariﬁed by low-speed centrifugation, and viral titers
of the samples were determined using MDCK cells as previously
described and expressed as log10 TCID50/g of tissue (Gillim-Ross et al.,
2008).
Cytokine analysis using Bio-plex and ELISA
The concentration of various cytokines or chemokines in clariﬁed
lung homogenates (10% wt./vol. in L15 media) harvested at speciﬁed
time points weremeasured by the Bio-plex Protein Array system (Bio-
rad, Hercules, CA). The assay was performed according to the
manufacturer's instructions, and the results were analyzed using the
Bio-Plex manager software. One hundred microliters of lung homog-
enate was used to measure IFN-β using a mouse IFN-β ELISA kit (PBL
Biomedical Laboratories, Piscataway, NJ).
Preparation of single-cell suspensions from lungs
Single-cell suspensions were prepared from lungs as previously
described (Lau et al., 2006). In brief, the lungs were harvested, ﬁnely
minced, and digested in RPMI-1640 medium containing 2 mg/mL of
collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) for
30 min at 37 °C. The collagenase A-treated tissues were then
homogenized by pressing against sieves (40 nm; BD Falcon) with
plastic plungers. Red blood cells were removed from the samples by
hypotonic shock with 0.15 M ammonium chloride in 17 mM Tris–HCl
for 5 min and were resuspended in PBS with 1% fetal calf serum (FCS)
for ﬂow cytometry analysis.
FACS analysis
Monoclonal antibodies (mAbs) against mouse CD3 (PerCP), CD4
(PE or ALPC), CD8 (PE or ALPC), CD11b (PerCP), CD11c (ALPC), Ly-6G
(PE), Ly-6G/C (PE), CD14 (FITC), CD19 (PE), and B220 (PerCP) were
purchased from BD PharMingen (San Diego, CA). Cell suspensions
were treated with Mouse Fc BlockTM (BD PharMingen, CA) on ice for
15 min before staining with various combinations of MAb for 30 min
on ice. Cells were washed twice with PBS with 1% FCS before analysis
on a FACSCalibur (BD Biosciences). A total of 80,000 events were
acquired for each lung sample. The data were analyzed by FlowJo
(Tree Star, Inc. Ashland, OR).NF-κB reporter gene assay
The mouse RIG-I and MDA-5 expressing plasmids were from
InvivoGen (San Diego, CA) and human embryonic kidney (HEK) 293
cells were transfected with the plasmids and the assay was performed
as previously described (Lau et al., 2009).
ELISA
ELISAs were performed with serum samples as described previ-
ously (Deliyannis et al., 1998) using BPL-inactivated A/Puerto Rico/8/
34 as the coating antigen. The optical density of each well was
measured at 405 nm using the SpectraMax M5 microplate reader
(Molecular Devices. Sunnyvale, CA).
Statistical analysis
The signiﬁcance of differences between different groups was
assessed by the Mann–Whitney test using Prism 5 (GraphPad
Software, Inc. San Diego, CA). In selected experiments, where the
sample size of each group was less than 5, the unpaired t test was
used. Reported p valuesb0.05 are considered signiﬁcantly different.
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